Hot Press News
- KRAFTON and ZeptoLab officially announce the launch of The Bullet Echo India game in India
- Perbacco, The Lodhi, Collaborates with Sopo Goa for a Unique Pop-Up Dining Experience
- Regain Has Launched Its IMAP Backup and Migration Tool
- Chai Sutta Bar backed Maatea introduces 'Maatea ki Mehfil' Initiative
- Kopyst Launches AI-Powered Video Documentation Feature for Seamless User Experience
- Karan Singh Nagra appointed as Marketing and Communications Manager of Hyatt Regency Dehradun, Resort & Spa
- Continental Technologies Ensure Greater Comfort and Safety in the Upper Mid-size Class
- TeamLease Degree Apprenticeship leads discussion on 'Innovation on Talent Supply Chain'
- AVTODOM Lamborghini organized a traditional spring motor rally in Moscow on April 19
- West Chester University Students Get a Lesson in Savings with Self Store USA's Special Summer Storage Program
- DocTube's Initiative on World Liver Day: Experts Unite to Combat Fatty Liver Disease
- Three NPOs win $1 million in grants from HCLTech for climate action projects across Americas
- CC Wholesale Clothing Introduces Trendy Plus Size Outerwear and Wholesale Hair Accessories
- Sandeep Marwah Inaugurates Tajurba MSME National Conference at New Delhi
- Spectra Global Ltd Introduces Classic Trading Accounts for Discerning Traders
 Mail to a Friend |
|
 Rate |
   |
Entry of Indian Cancer Generics in the US - Driving Global Market
2024-04-22 12:28:26
Industry
1412
?Approval of Indian cancer generics in the US have opened array of opportunities for the growth of Global Cancer Generics Market?, says RNCOS.
In recent times, it has been observed that generic cancer drugs are facing severe shortage especially in the US. According to our report, ?Global Cancer Generics Market Forecast to 2022?, a major reason for the shortage includes lack of incentive to producers for manufacturing low-cost generics, which presently invokes small profit margins.
Recently, an India based drug firm Dr Reddy?s Laboratories launched its generic Decitabine injection used in the treatment of cancer in the US market following approval by the USFDA of its Abbreviated New Drug Applications (ANDA). Similarly, in October 2016, Shilpa Medicare Ltd. received an approval from USFDA for generic Azacitidine injection. This generic drug is used for the treatment of myelodysplastic syndrome. Furthermore, in December 2015, Sun Pharmaceuticals received USFDA approval for the generic version of Novartis AG?s blockbuster cancer drug Gleevec for the treatment of chronic myeloid leukaemia. The Sun Pharma, being the first to file an ANDA for generic Gleevec, was eligible for a 180-day marketing exclusivity in the US, giving the company a headstart before other pharmaceutical companies could also start manufacturing the same drug.
All these approvals have given a boost to the morale of Indian cancer generic manufacturers. Other pharmaceutical companies have also entered this field looking at its vast scope in the future.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM862.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
ABOUT RNCOS
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.
Company :-RNCOS E-Services Pvt. Ltd.
User :- Shushmul Maheshwari
Email :-press@rncos.com
Phone :-24700-24700-4224700
Mobile:- 120-4224700
Url :- http://www.rncos.com
